{"id":13403,"date":"2010-10-28T10:00:00","date_gmt":"2010-10-28T08:00:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/molmed-corre-a-piazza-affari\/"},"modified":"2010-10-28T10:00:00","modified_gmt":"2010-10-28T08:00:00","slug":"molmed-corre-a-piazza-affari","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/molmed-corre-a-piazza-affari\/","title":{"rendered":"MolMed runs to Piazza Affari"},"content":{"rendered":"

 <\/p>\n

(Teleborsa) - Rome, Oct. 27 - MolMed earnings day in Piazza Affari. The shares of the biotech company jumped by 3.91%s, changing to 0.43 euros per share. The earnings are even more surprising if one considers that the stock travels against the Italian indices in red. The news that MolMed has started the new experimental study on an experimental anticancer biopharmaceutical NGR-hTNF for the treatment of soft tissue sarcomas triggered the interest of Milanese investors in the stock. The study, according to a note, foresees the enrollment of 96 patients and will test the administration of NGR-hTNF as monotherapy or in combination with doxorubicin.<\/p>\n

 <\/p>\n

 \"\"                     \"\"<\/p>\n

Berlusconi and Molmed: history of a deal?<\/h1>\n
It was March 20, when in front of what they called "a million" people, the Prime Minister<\/strong> promised to permanently defeat the cancer<\/strong>. Over the course of three years. It was the manifestation of PDL <\/strong>called following the exclusion from the list Powders<\/strong> in the regional elections of Lazio: the prime minister decided to focus on a delicate topic to involve masses of desperate people in an extreme attempt to raise the boat of an electoral competition that seemed to be turning for the worse, after the chaos of the lists. This did not happen, and the disease was not cited for one case.<\/p>\n

A few days ago, in fact, it was discovered that the Silvio Berlusconi <\/strong>raised its stake in the MolMed<\/strong>, the Molecular Medicine Spa, through the Fininvest<\/strong>. His son Luigi, 21, placed on the board of directors. According to reports from the agency Bloomberg<\/strong>, MolMed is a pharmaceutical company that is studying new anticancer drugs. Two, to be exact: one against the main types of cancer, the other with a tonic function for the immune system debilitated by leukemia.<\/p>\n

In the meantime, allusions abound in the press and on the internet: it sounds strange how Berlusconi becomes the majority shareholder of the company that has been working on cancer medicines since December, in the face of public declarations in March. With an aggravating circumstance: in the new book by Wasp <\/strong>the prime minister admits that he underwent surgery for cancer. \u201cI'm not even sure that surgery was necessary. Get checked by three different doctors before having surgery,\u201d the Prime Minister<\/strong>. For many, an almost promotional message for a drug that probably won't require further surgery to be able to work.<\/p>\n

But that's not enough: there are not a few who point out that the criticisms of theNational Medical Oncology Association<\/strong> complain about the new cuts in the national health service, which will not allow doctors to provide adequate treatment for cancer patients. As if the AR was waiting to solve the problem<\/p>","protected":false},"excerpt":{"rendered":"

  (Teleborsa) – Roma, 27 ott – Giornata di guadagni per MolMed a Piazza Affari. Le azioni dell’azienda biotecnologica fanno un balzo del 3,91%scambiando a 0,43 euro per azione. I guadani sono ancor più sorpeendenti si si considera che il titolo viaggia in controtenenza ad indici italiani in rosso. A far scattare l’interese degli investitori …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13403","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13403"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13403\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}